Ajanta Pharma Limited Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2018
January 30, 2019 at 08:20 am
Share
Ajanta Pharma Limited announced unaudited consolidated earnings results for the third quarter and nine months ended December 31, 2018. For the quarter, the company announced total income of INR 4,895.2 million compared to INR 6,022.0 million a year ago. Profit for the period was INR 669.0 million compared to INR 1,474.7 million a year ago. Basic and diluted earnings per share was INR 7.60 compared to INR 16.76 per basic share and INR 16.75 per diluted share reported last year. Revenue from operations was INR 4,851.1 million against INR 5,870.5 million reported last year.
For the nine months, the company announced total income of INR 15,596.6 million compared to INR 16,206.4 million a year ago. Profit for the period was INR 2,980.8 million compared to INR 3,741.5 million a year ago. Basic earnings per share was INR 33.87 compared to INR 42.51 a year ago. Diluted earnings per share was INR 33.86 compared to INR 42.50 a year ago. Revenue from operations was INR 15,402.1 million against INR 16,005.5 million reported last year.
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
AJANTA PHARMA LIMITED 
